Provision of Multidrug-resistant tuberculosis (MDR-TB) and Extensively drug-resistant tuberculosis (XDR-TB) treatment

NHS England are inviting Expressions of Interests from suitably experienced, competent and skilled providers wishing to demonstrate compliance with the requirements as set out in this notice for the provision of Bedaquiline and Delamanid for defined patients with Multidrug-Resistant / Extensively Drug-resistant Tuberculosis . This opportunity was also advertised during December 2015 (OJEU reference: 2015/S243-441645).

However, this is an additional notice for the same procurement exercise in order to allow a more reasonable time for interested providers to express their interest. Providers who expressed their interest in the original notice do not need to express their interest again in order to be considered) Drug resistance represents a major challenge to TB control.

Multidrug-resistant tuberculosis (MDR-TB) is a form of tuberculosis that is resistant to, at least two anti- TB drugs, rifampicin and isoniazid; extensively drug-resistant tuberculosis (XDR-TB) is a form of TB that is MDR TB with additional resistance to any fluoroquinolone and to at least one of three injectable anti-TB drugs (i.e., kanamycin, capreomycin, or amikacin), and associated with high mortality, particularly among people living with human immunodeficiency virus (PLHIV). NHS England will commission a provider(s) of bedaquiline and delamanid as an adjuvant for the treatment of proven multi-drug resistant and extensively drug-resistant tuberculosis (MDR- and XDR-TB) for adult patients who have proven MDR- or XDR-TB and where there is documented evidence of resistance to fluoroquinolones or intolerance to second line drugs.

Interested providers must ensure they meet the relevant criteria in order to express their interest. Please respond by 12 noon on the 2nd February 2016